Buy this Article for $7.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, RN

Abstract

* Denosumab has been approved under the trade name Xgeva for use in patients with metastasized cancer to help prevent bone-related events.

 

* Clinical trials found denosumab to be superior to zoledronic acid in delaying the onset of such events in patients with metastatic breast or prostate cancer.

 

* Serious adverse effects of denosumab include hypocalcemia and osteonecrosis of the jaw.